Program
emraclidine
Also written as “Emraclidine”, “CVL-231” and “Emraclidine 30 mg”.
In AbbVie's pipeline, M4 PAM
. Its studies are mostly in Schizophrenia · Alzheimer Disease · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 172 open or running | phase 2since Jan 27, 2022 | Oct 16, 2019 | Dec 2026phase 1 · NCT07219030 |
| Pfizer | 10 open or running | phase 1since Jul 6, 2017 | Jul 6, 2017 | none ahead |
- Named in AbbVie’s own pipeline as
Emraclidine
, phase 2, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jul 6, 2017.
- Oct 16, 2019AbbVie's first study: phase 1 study in SchizophreniaNew to AbbVieAbbVie · NCT04136873 · 130 enrolled · United States
- Feb 1, 2021Phase 1 study in SchizophreniaAbbVie · NCT04787302 · 15 enrolled · United States, Belgium
- Nov 1, 2021Phase 1 study in SchizophreniaAbbVie · NCT05106309 · 16 enrolled · United States
- Jan 27, 2022Phase 1 study in SchizophreniaAbbVie · NCT05245539 · 151 enrolled · United States
- Jan 27, 20222 phase 2 studies in SchizophreniaAbbVie · NCT05227703, NCT05227690
- Jun 29, 2022Phase 2 study in SchizophreniaAbbVie · NCT05443724 · 698 enrolled · United States, Bulgaria, Hungary and more
- Dec 1, 2022Phase 1 study in Healthy ParticipantsAbbVie · NCT05644977 · 17 enrolled · United States
- Jun 13, 20233 phase 1 studiesAbbVie · NCT05915546, NCT05933187, NCT05935033
- Jul 2, 2023Phase 1 study in Renal InsufficiencyAbbVie · NCT05940402 · 58 enrolled · United States
- Mar 1, 2024Phase 1 study in Healthy ParticipantsAbbVie · NCT06301971 · 8 enrolled · United States
- Apr 11, 2024Phase 1 study in Healthy ParticipantsAbbVie · NCT06366243 · 20 enrolled · United States
- Aug 22, 2025Phase 2 study in SchizophreniaAbbVie · NCT07145918 · 268 planned · United States
- Oct 17, 2025Phase 1 study in Healthy VolunteerAbbVie · NCT07219030 · 52 planned · United States
- May 8, 2026Phase 1 study in Healthy VolunteersAbbVie · NCT07587008 · 12 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Healthy VolunteerAbbVie · NCT07219030
- Feb 2028Primary completion: phase 2 study in SchizophreniaAbbVie · NCT07145918
TargetBeta
“M4 PAM”the company's pipeline, read by Claude · source
Other programs on CHRM4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| xanomelinerule | Bristol-Myers Squibb | phase 4 | 38 |
| GXV-813 | Novartis | phase 2 | 1 |
| ABBV-1042 | AbbVie | phase 1 | 1 |
| BMS-986521 | Bristol-Myers Squibb | phase 1 | 1 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07587008Healthy Volunteers · United States | 1 | Completed | AbbVie | Jul 17, 2026 | 12 |
| NCT07219030Healthy Volunteer · United States | 1 | Recruiting | AbbVie | Dec 2026 | 52 |
| NCT07145918Schizophrenia · United States | 2 | Recruiting | AbbVie | Feb 2028 | 268 |
| NCT06366243Healthy Participants · United States | 1 | Completed | AbbVie | Jun 20, 2024 | 20 |
| NCT06301971Healthy Participants · United States | 1 | Completed | AbbVie | Apr 4, 2024 | 8 |
| NCT05940402Renal Insufficiency · United States | 1 | Completed | AbbVie | Dec 19, 2024 | 58 |
| NCT05935033Hepatic Impairment · United States | 1 | Completed | AbbVie | Feb 21, 2025 | 38 |
| NCT05933187Healthy Participants · United States | 1 | Completed | AbbVie | Sep 12, 2023 | 15 |
| NCT05915546Healthy · United States | 1 | Completed | AbbVie | Jul 26, 2023 | 16 |
| NCT05644977Healthy Participants · United States | 1 | Completed | AbbVie | Apr 14, 2025 | 17 |
| NCT05443724Schizophrenia · United States, Bulgaria, Hungary and more | 2 | Terminated | AbbVie | Jun 25, 2025 | 698 |
| NCT05245539Schizophrenia · United States | 1 | Completed | AbbVie | Oct 19, 2022 | 151 |
| NCT05227703Schizophrenia · United States, Bulgaria, Hungary | 2 | Completed | AbbVie | Aug 15, 2024 | 391 |
| NCT05227690Schizophrenia · United States, Bulgaria | 2 | Completed | AbbVie | Aug 23, 2024 | 385 |
| NCT05106309Schizophrenia · United States | 1 | Completed | AbbVie | Feb 24, 2022 | 16 |
| NCT04787302Schizophrenia · United States, Belgium | 1 | Completed | AbbVie | Jul 14, 2023 | 15 |
| NCT04136873Schizophrenia · United States | 1 | Completed | AbbVie | May 7, 2021 | 130 |
| NCT03217604Healthy Volunteers · Belgium | 1 | Completed | Pfizer | Feb 1, 2018 | 17 |
How it is read
Names in the registry
- “Emraclidine”, 9 entries
- “CVL-231”, 5 entries
- “Emraclidine 30 mg”, 3 entries
- “Emraclidine 15 mg”, 1 entry
- “Emraclidine 10 mg”, 1 entry
Codes read as this program: CVL231.
Conditions, from the studies’ own filings
- Schizophrenia, 8 studies
- Alzheimer Disease, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.